2185857-97-8
2185857-97-8 structure
- Name: PF-06873600
- Chemical Name: PF-06873600
- CAS Number: 2185857-97-8
- Molecular Formula: C20H27F2N5O4S
- Molecular Weight: 471.52
- Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
- Create Date: 2019-02-14 07:25:49
- Modify Date: 2024-01-09 09:35:06
-
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].
| Name | PF-06873600 |
|---|
| Description | PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CDK2:0.09 nM (Ki) CDK4:0.13 nM (Ki) CDK6:0.16 nM (Ki) |
| In Vitro | PF-06873600 (Example 8) is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity[1]. PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells[2]. |
| References |
[1]. US 2018/0044344 A1. [2]. NCI Drug Dictionary |
| Molecular Formula | C20H27F2N5O4S |
|---|---|
| Molecular Weight | 471.52 |
| Storage condition | 2-8℃ |